Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for ...

Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.

人民网重庆10月22日电 近日，重庆医科大学附属第二医院(以下简称“重医附二院”)脂质研究中心丁银元特聘教授团队在国际知名期刊《Advanced Science》(中国科学院一区TOP期刊)上发表了题为“Loss of LRP1 Promotes ...

In this medical fiction tale, a journalist's attempt to expose what he believes to be a secret gender-affirming care clinic in a hospital basement turns deadly.

KOCHI: George (name changed), was 55-years-old when he was diagnosed with fatty liver. Since he was a teetotaller, he did not ...

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic ...

Cancer vaccines train the immune system to combat foreign invaders like tumours, enhancing the body's ability to recognize ...

Researchers at Weill Cornell Medicine have made a breakthrough in the fight against liver cancer, by identifying a biomarker ...

【导读】肝细胞癌（HCC）是肝脏最常见的恶性肿瘤，预后不佳。跨膜蛋白209（TMEM209）参与多种生物学过程，如物质转运和信号转导，在肿瘤组织中大量表达。然而，TMEM209与HCC之间的关系尚未完全阐明。10月16日，郑州大学郭文治研究团队在期刊 ...

A group of researchers at VCU Massey Comprehensive Cancer Center was awarded $13 million by the National Cancer Institute.